
About Triochem Products
Triochem Products is a publicly listed company based in Mumbai (India) founded in 1972. Manufacturer and exporter of pharmaceutical bulk drugs and chemicals in India. It operates on a B2B model. The company has 10 employees. Its Indian entity Triochem Products Limited reported revenue of βΉ12.03 Cr. Triochem Products offers products and services including Pharmaceutical Bulk Drugs, APIs, and Chemicals. Its focus areas include Pharmaceuticals, Bulk Drugs and APIs and Chemicals. Similar companies include Laurus Labs, Symbiotec and SeQuent; 2 of its 3 listed similar companies have raised funding.
Company details
Triochem Products Ltd., established in 1972, manufactures and exports pharmaceutical bulk drugs, APIs, and chemicals from India. Headed by Mr. Ramu S. Deora, it focuses on quality products at competitive prices with timely delivery to exceed client expectations. Operations are based in Mumbai and Ambernath, Maharashtra, serving global business partners.
- Headquarters Mumbai, India
- Employees 10
- Stage Public
- SectorsHealthcare
- Emailβ’β’β’β’β’β’β’β’
- Website triochemproducts.com
- Legal Name Triochem Products Limited
- Date of Incorporation 07 Jan, 1972
- Jurisdiction Mumbai, Maharashtra, India
- Market Cap₹0.43 Cr
TRIPR · BSE
- Share Price₹17.40
0.00% today
- EBITDA−₹1.36 Cr
FY 2025-26
- Net Profit−₹5.93 Cr
FY 2025-26 · -597.7% YoY
- ROE-34.6%
ROCE -4.3%
- Employee Count10
Associated legal entities of Triochem Products
Triochem Products operates through Triochem Products Limited, a listed company (active). Its filings, financials, charges and directors are on the company page.
| Legal entity | Status | Incorporated | Registered in | Revenue (FY 2026) | Employees | Directors | Company page |
|---|---|---|---|---|---|---|---|
| Triochem Products Limited Listed CIN L24249MH1972PLC015544 | Active | 07 Jan 1972 | Mumbai, Maharashtra | ₹12.0 Cr | 10 | 9 | View details |
Products & Services of Triochem Products
Triochem Products offers a comprehensive portfolio of products and services, including Pharmaceutical Bulk Drugs, APIs, and Chemicals.
Production of bulk drugs for pharmaceutical applications
Active ingredients used in pharmaceutical drugs
Various chemicals for export and industrial use
Board of directors of Triochem Products Limited (Triochem Products)
Triochem Products Limited is the primary company behind Triochem Products. The board of Triochem Products Limited currently have 6 directors; the longest-serving is Ramu Sitaram Deora, appointed in 1975. 4 earlier directors have ceased.
| Director | Designation | Appointed | Tenure | Entity |
|---|---|---|---|---|
| Ramu Sitaram Deora DIN 00312369 | Director | 30 Jun 1975 | 51 yrs 4 mo | Triochem Products Limited |
| Shyam Sundar Sharma DIN 01457322 | Director | 28 May 1985 | 41 yrs 5 mo | Triochem Products Limited |
| Grace Ramu Deora DIN 00312080 | Director | 30 Mar 2015 | 11 yrs 7 mo | Triochem Products Limited |
| Rajesh Ramu Deora DIN 00312316 | Director | 28 May 2019 | 7 yrs 5 mo | Triochem Products Limited |
| Vipul Amul Desai DIN 02074877 | Director | 29 Mar 2025 | 1 yr 7 mo | Triochem Products Limited |
| Shailendra Mishra DIN 07373830 | Director | 29 Mar 2025 | 1 yr 7 mo | Triochem Products Limited |
IPO & Listings of Triochem Products
Triochem Products is a publicly listed company on the BSE with ticker symbol TRIPR in India, operating in the Pharmaceuticals sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- Listed onBSE: TRIPR
- Listed entityTriochem Products Limited
- Exchange sectorPharmaceuticals
Financials of Triochem Products
Exchange-reported figures of Triochem Products Limited, the listed company behind Triochem Products (BSE: TRIPR).
Financial Highlights
FY 2025-26 Β· StandaloneRevenue vs Net Profit ₹ Cr
Margin trends
Financial summary ₹ Cr
| Metrics | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 8.82 | 13.94 | 20.03 |
| Revenue growth | - | - | - | -100.0% | -36.7% | -30.4% | - |
| EBITDA | (1.36) | (1.21) | (2.27) | (1.35) | 1.33 | (0.37) | 4.55 |
| EBITDA margin | - | - | - | - | +15.1% | -2.7% | +22.7% |
| Profit before tax | 10.52 | (0.24) | (1.33) | (1.18) | 1.75 | (0.59) | 4.55 |
| Net profit | (5.93) | (0.85) | (0.12) | (0.97) | 1.31 | (0.45) | 3.40 |
| Net profit margin | - | - | - | - | +14.9% | -3.2% | +17.0% |
| EPS (βΉ) | 325.33 | (16.34) | (41.36) | (36.13) | 53.99 | (18.24) | 138.89 |
| Balance sheet | |||||||
| Total assets | 20.65 | 13.67 | 14.62 | 11.60 | 13.05 | 11.71 | 14.68 |
| Net worth | 20.65 | 13.67 | 14.63 | 11.60 | 13.05 | 11.72 | 12.18 |
| Total debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 2.50 |
| Cash & bank | 11.73 | 0.91 | 0.54 | 0.96 | 11.81 | 8.20 | 0.55 |
| Net working capital | 12.96 | 2.31 | 2.45 | 1.04 | 11.83 | 10.61 | 13.51 |
| Cash flow | |||||||
| Cash from operations | (2.87) | 0.20 | (3.76) | (1.58) | 3.47 | 10.25 | 3.82 |
| Cash from investing | 13.70 | 0.17 | 3.34 | (9.27) | 0.16 | 0.00 | (0.03) |
| Cash from financing | 0.00 | 0.00 | 0.00 | 0.00 | (0.02) | (2.61) | (3.49) |
| Particulars | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other income | 0.17 | 0.17 | 11.29 | 0.22 | 0.30 | 0.22 | 0.32 | 0.46 |
| Total expenses | 0.06 | 0.04 | 0.22 | 0.38 | 0.42 | 0.36 | 0.33 | 0.59 |
| EBITDA | (0.06) | (0.04) | (0.22) | (0.38) | (0.42) | (0.36) | (0.33) | (0.59) |
| Depreciation | 0.00 | 0.00 | 0.00 | 0.01 | 0.02 | 0.02 | 0.02 | 0.04 |
| Interest | 0.00 | 0.00 | 0.08 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Profit before tax | 0.11 | 0.13 | 10.99 | (0.17) | (0.14) | (0.16) | (0.03) | (0.17) |
| Tax | 0.02 | 0.03 | 2.66 | (0.04) | 0.05 | (0.12) | 0.42 | (0.25) |
Financial Statements
| Particulars | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other income | 0.17 | 0.17 | 11.29 | 0.22 | 0.30 | 0.22 | 0.32 | 0.46 |
| Total expenses | 0.06 | 0.04 | 0.22 | 0.38 | 0.42 | 0.36 | 0.33 | 0.59 |
| EBITDA | (0.06) | (0.04) | (0.22) | (0.38) | (0.42) | (0.36) | (0.33) | (0.59) |
| Depreciation | 0.00 | 0.00 | 0.00 | 0.01 | 0.02 | 0.02 | 0.02 | 0.04 |
| Interest | 0.00 | 0.00 | 0.08 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Profit before tax | 0.11 | 0.13 | 10.99 | (0.17) | (0.14) | (0.16) | (0.03) | (0.17) |
| Tax | 0.02 | 0.03 | 2.66 | (0.04) | 0.05 | (0.12) | 0.42 | (0.25) |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 8.82 | 13.94 | 20.03 |
| Revenue growth | - | - | - | -100.0% | -36.7% | -30.4% | - |
| Other income | 12.03 | 1.05 | 1.03 | 0.28 | 0.56 | 0.13 | 0.47 |
| Total expenses | 1.36 | 1.21 | 2.27 | 1.35 | 7.49 | 14.31 | 15.48 |
| Employee cost | 0.53 | 0.59 | 0.47 | 0.52 | 0.50 | 0.67 | 0.82 |
| EBITDA | (1.36) | (1.21) | (2.27) | (1.35) | 1.33 | (0.37) | 4.55 |
| EBITDA margin | - | - | - | - | +15.1% | -2.7% | +22.7% |
| Depreciation | 0.05 | 0.08 | 0.09 | 0.11 | 0.12 | 0.14 | 0.17 |
| Interest | 0.10 | 0.00 | 0.00 | 0.00 | 0.02 | 0.21 | 0.30 |
| Profit before tax | 10.52 | (0.24) | (1.33) | (1.18) | 1.75 | (0.59) | 4.55 |
| Tax | 2.54 | 0.15 | (0.32) | (0.29) | 0.44 | (0.14) | 1.15 |
| Net profit | (5.93) | (0.85) | (0.12) | (0.97) | 1.31 | (0.45) | 3.40 |
| Net profit margin | - | - | - | - | +14.9% | -3.2% | +17.0% |
| EPS (βΉ) | 325.33 | (16.34) | (41.36) | (36.13) | 53.99 | (18.24) | 138.89 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Equity & liabilities | |||||||
| Share capital | 0.25 | 0.25 | 0.25 | 0.25 | 0.25 | 0.25 | 0.25 |
| Reserves & surplus | 20.40 | 13.42 | 14.38 | 11.35 | 12.80 | 11.47 | 11.93 |
| Shareholders' funds (net worth) | 20.65 | 13.67 | 14.63 | 11.60 | 13.05 | 11.72 | 12.18 |
| Secured loans | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.25 |
| Unsecured loans | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.25 |
| Total debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 2.50 |
| Total liabilities | 20.65 | 13.67 | 14.62 | 11.60 | 13.05 | 11.71 | 14.68 |
| Assets | |||||||
| Gross block | 0.00 | 2.03 | 2.03 | 2.03 | 2.02 | 1.97 | 1.95 |
| Net block | 0.00 | 0.60 | 0.68 | 0.77 | 0.87 | 0.94 | 1.06 |
| Capital work in progress | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.03 | 0.03 |
| Investments | 7.89 | 10.63 | 11.07 | 9.42 | 0.00 | 0.00 | 0.00 |
| Inventories | 0.00 | 0.00 | 0.05 | 0.05 | 0.05 | 0.85 | 1.55 |
| Sundry debtors | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.39 | 12.40 |
| Cash & bank balances | 11.73 | 0.91 | 0.54 | 0.96 | 11.81 | 8.20 | 0.55 |
| Loans & advances | 1.26 | 1.62 | 2.13 | 0.27 | 0.18 | 0.56 | 0.86 |
| Total current assets | 12.99 | 2.53 | 2.72 | 1.28 | 12.04 | 11.00 | 15.36 |
| Total current liabilities | 0.03 | 0.22 | 0.27 | 0.24 | 0.21 | 0.39 | 1.85 |
| Net working capital | 12.96 | 2.31 | 2.45 | 1.04 | 11.83 | 10.61 | 13.51 |
| Total assets | 20.65 | 13.67 | 14.62 | 11.60 | 13.05 | 11.71 | 14.68 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Opening cash | 0.91 | 0.54 | 0.96 | 11.81 | 8.20 | 0.55 | 0.25 |
| Net cash from operating activities | (2.87) | 0.20 | (3.76) | (1.58) | 3.47 | 10.25 | 3.82 |
| Net cash from investing activities | 13.70 | 0.17 | 3.34 | (9.27) | 0.16 | 0.00 | (0.03) |
| Net cash from financing activities | 0.00 | 0.00 | 0.00 | 0.00 | (0.02) | (2.61) | (3.49) |
| Net change in cash | 10.82 | 0.37 | (0.42) | (10.85) | 3.61 | 7.64 | 0.30 |
| Closing cash | 11.73 | 0.91 | 0.54 | 0.96 | 11.81 | 8.20 | 0.55 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Growth | |||||||
| Sales growth | - | - | - | -100.0% | -36.7% | -30.4% | - |
| EBITDA growth | -12.4% | +46.7% | -68.2% | -201.5% | +459.5% | -108.1% | - |
| PBT growth | +9998.0% | +82.0% | -12.7% | - | +9998.0% | - | +333.3% |
| Net income growth | -597.7% | -608.3% | +87.6% | -174.1% | +391.1% | -113.2% | - |
| Revenue CAGR (3Y) | - | -100.0% | -100.0% | -100.0% | -10.6% | -26.4% | +3.5% |
| EBITDA CAGR (3Y) | +0.3% | - | +83.1% | - | -7.1% | - | +66.3% |
| Profitability & leverage | |||||||
| Net income margin | - | - | - | - | +14.9% | -3.2% | +17.0% |
| Return on capital employed | -4.3% | -3.3% | -2.7% | -9.5% | +14.4% | -2.8% | +33.2% |
| Return on net worth | -34.6% | -6.1% | -0.9% | -7.2% | +10.7% | -3.8% | +32.4% |
| Debt / equity | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.10 | 0.40 |
| Long-term debt / equity | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest cover | -7.09 | 0.00 | 0.00 | 0.00 | 1.65 | -41.18 | 6.85 |
| Efficiency & per share | |||||||
| Fixed asset turnover | 0.00 | 0.00 | 0.00 | 0.00 | 4.42 | 7.11 | 10.27 |
| Inventory turnover | 0.00 | 0.00 | 0.00 | 0.00 | 19.60 | 11.62 | 3.60 |
| Debtors turnover | 0.00 | 0.00 | 0.00 | 0.00 | 12.69 | 2.02 | 2.55 |
| EPS (βΉ) | 325.33 | (16.34) | (41.36) | (36.13) | 53.99 | (18.24) | 138.89 |
| Dividend per share (βΉ) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Book value per share (βΉ) | 842.78 | 557.83 | 596.74 | 473.36 | 532.51 | 478.04 | 497.00 |
Similar companies to Triochem Products
Triochem Products has 3 listed similar companies in our database, 2 of them funded. They include Laurus Labs, Symbiotec and SeQuent.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| lauruslabs.com | 2005 | Hyderabad, India | $229.73M | 6,035 | Pharmaceutical and biotechnology company | |
| symbiotec.in | 2002 | Indore, India | $61.01M | 1,822 | Non-sterile steroid hormone-based APIs and intermediates are manufactured. | |
| sequent.in | 2002 | Bengaluru, India | APIs are developed and manufactured for therapeutic areas. |
Detailed similar companies of Triochem Products
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track β from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Triochem Products
Complete news archive for Triochem Products
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Triochem Products
Triochem Products was founded in 1972.
Triochem Products is headquartered in Mumbai, India. It is registered at Mumbai, Maharashtra, India.
Triochem Products has 10 employees.
The primary company behind Triochem Products, Triochem Products Limited, reported revenue of βΉ12.03 Cr for FY 2026, up 9997% year on year.
Triochem Products Ltd., established in 1972, manufactures and exports pharmaceutical bulk drugs, APIs, and chemicals from India. Headed by Mr. Ramu S. Deora, it focuses on quality products at competitive prices with timely delivery to exceed client expectations. Operations are based in Mumbai and Ambernath, Maharashtra, serving global business partners.
Triochem Products's top competitors include Laurus Labs, Symbiotec and SeQuent.
Triochem Products offers Pharmaceutical Bulk Drugs, APIs, and Chemicals.
Yes, Triochem Products is publicly traded on BSE under the ticker symbol TRIPR.
Triochem Products operates through Triochem Products Limited.
The legal entities of Triochem Products currently have 8 directors, including Grace Ramu Deora, Ramu Sitaram Deora, Shyam Sundar Sharma and others.
